Home / Search Results

Search Results

You searched for:

    Displaying results 1 - 20 of 33
  • 1
  • 2
  • »
ACCC recently announced a collaboration with the Digital Medicine Society on a project to develop a risk prediction tool for cytokine release syndrome.
September 7, 2023
Hear patient advocacy professionals discuss the impact of using patient-centered vocabulary during precision medicine conversations.
ACCCBuzz spoke with Luis E. Raez, MD, FACP, FCCP, to learn more about the importance of closing the gap in access to biomarker testing and strategies to improve equity and inclusion in precision medicine.
With the variety of models and titles that have emerged under precision medicine stewardship, learn how one cancer program is breaking down the this complex landscape into streamlined workflows to improve efficiency and better support growing test volumes.
ACCC President Dr. David R. Penberthy's final Tech Talk featured 4 panelists, who shared their perspectives on how technologies like artificial intelligence, machine learning, and the use of big data are currently impacting cancer care delivery, as well as their vision of the ideal future state.
ACCC conducted a comprehensive survey and a series of four focus groups to explore current attitudes, beliefs, and concerns related to multi-cancer early detection.
ACCC shares how a precision medicine steward—a dedicated navigator focused specifically on biopsy samples and biomarker testing processes and results—can make a daunting biomarker testing process incredibly efficient for cancer programs and practices everywhere.
Dr. John Strickler from Duke Cancer Institute sat down with ACCCBuzz to talk about molecular profiling and data, including the cancer institute's own journey in oncology precision medicine.
Introduced in 2021, the Cancer Patient Equity Act seeks to provide coverage of certain cancer diagnostic and laboratory tests under Medicare, Medicaid, and the Children's Health Insurance Program, and more.
ACCCBuzz shares highlights from the NCCN Policy Summit: Reducing the Cancer Burden through Prevention and Early Detection, highlighting the real impacts felt by patients and providers in cancer risk identification and reduction.
Care optimization is everything in today’s rapidly changing healthcare landscape. Learn how ACCC's nationwide quality improvement (QI) initiative helped Southern Ohio Medical Center Cancer Center develop and implement plans to support the optimization of care for patients diagnosed with Stages III and IV non-small cell lung cancer (NSCLC).
On September 16, the National Comprehensive Cancer Network convened experts and stakeholders in D.C. for a policy summit spotlighting today’s cancer screening and prevention landscape. Learn what speakers discussed, including what changes need to happen to create an equitable future for all people at risk—or not—for cancer.
Communities around the globe recognize August 1 as World Lung Cancer Day—a day to commemorate, educate, and support individuals and families impacted by lung cancer. Read highlights on a few ACCC initiatives that are helping cancer care teams better support their patients with this disease.
To fill a care gap, The James Cancer Hospital opened a new set of front doors to its facility—The James Cancer Diagnostic Center—to ensure all patients with a concern for cancer could be quickly evaluated, even if they didn’t have a confirmed diagnosis.
Measurable residual disease (MRD) has gained traction as a compelling marker for disease status across various hematologic malignancies, including multiple myeloma. Learn how MRD is uniquely suited to help evaluate the depth of treatment response.
With data already demonstrating the role of MRD for CLL response assessment and prognosis, cancer programs should prepare themselves for implementation of MRD testing for appropriate patients.
Advocating on behalf of their patients and programs, ACCC members from 14 states participated in Virtual Hill Day, speaking with Congress and their staff on key legislation asks regarding access to care, telehealth, prior authorizations, and more.
Testing for measurable residual disease can shape treatment choices and patient management to achieve better outcomes, and the need persists for members of the multidisciplinary cancer care team to better understand the purpose, use, and significance of this testing in all cancer treatment settings.
Carolina Blood and Cancer Care Associate's No One Left Alone (or NOLA) initiative is a multi-phase pilot program aimed at lessening disparities in cancer care in three key areas: care access, biomarker testing, and clinical trials.
A mix-method approach to understand clinician use of biomarker testing for patients with non-small cell lung cancer.
    Displaying results 1 - 20 of 33
  • 1
  • 2
  • »